• Lars M Asmis, Andreas Serra, Alexander Krafft, Abraham Licht, Elke Leisinger, Jana Henschkowski-Serra, Michael T Ganter, Steffen Hauptmann, Marianne Tinguely, and Johanna A Kremer Hovinga.
• From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland.
• N. Engl. J. Med. 2022 Dec 22; 387 (25): 235623612356-2361.

AbstractA 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 deficiency when she presented with an acute episode in the 30th week of her second pregnancy. When the acute episode of hereditary TTP became plasma-refractory and fetal death was imminent, weekly injections of recombinant ADAMTS13 at a dose of 40 U per kilogram of body weight were initiated. The patient's platelet count normalized, and the growth of the fetus stabilized. At 37 weeks 1 day of gestation, a small-for-gestational-age boy was delivered by cesarean section. At the time of this report, the patient and her son were well, and she continued to receive injections of recombinant ADAMTS13 every 2 weeks. (Funded by the Swiss National Science Foundation.).Copyright © 2022 Massachusetts Medical Society.

23 keywords...

hide…